Risk factors of flare in patients with systemic lupus erythematosus after glucocorticoids withdrawal. A systematic review and meta-analysis
Open Access
- 7 January 2022
- journal article
- review article
- Published by BMJ in Lupus Science & Medicine
- Vol. 9 (1) , e000603
Abstract
Objective Glucocorticoids (GC) withdrawal is part of the targets in current recommendations for SLE, but relapse is the most worrying issue. We aimed to investigate the predictors for flare in patients with SLE after GC withdrawal. Methods We systematically searched PubMed, EMBASE and Cochrane Library as well as Scopus databases up to 9 July 2021 for studies concerning predictive factors of relapses in patients with SLE after GC cessation. Pooled OR and 95% CI were combined using a random-effects or fixed-effects model. Results 635 patients with SLE with GC discontinuation in 9 publications were eligible for the final analysis. Of them, 99.5% patients were in clinical remission before GC withdrawal. Serologically active yet clinically quiescent (SACQ) was associated with an increased risk of flare after GC withdrawal (OR 1.78, 95% CI (1.00 to 3.15)). Older age and concomitant use of hydroxychloroquine (HCQ) trended towards decreased risk of flare (weighted mean difference (WMD) −2.04, 95% CI (−4.15 to 0.06) for age and OR 0.50, 95% CI (0.23 to 1.07) for HCQ), yet not statistically significant. No significant association was observed regarding gender (pooled OR 1.75; 95% CI (0.59 to 5.20)), disease duration (WMD −11.91, 95% CI (−27.73 to 3.91)), remission duration (WMD −8.55, 95% CI (−33.33 to 16.23)), GC treatment duration (WMD −10.10, 95% CI (−64.09 to 43.88)), concomitant use of immunosuppressant (OR 0.86, 95% CI (0.48 to 1.53)). Conclusion Younger age and SACQ were potential risk factors of SLE flare among patients who discontinued GC. HCQ, but not immunosuppressant might prevent flare. GC withdrawal should be done with caution in this subgroup of patients.Keywords
This publication has 30 references indexed in Scilit:
- Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus—the Hopkins Lupus CohortLupus Science & Medicine, 2015
- What happens after complete withdrawal of therapy in patients with lupus nephritis.2013
- Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort studyRheumatology, 2013
- Baseline Predictors of Systemic Lupus Erythematosus Flares: Data From the Combined Placebo Groups in the Phase III Belimumab TrialsArthritis & Rheumatism, 2013
- Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent periodArthritis Care & Research, 2011
- Soy intake is associated with lower lung cancer risk: results from a meta-analysis of epidemiologic studiesThe American Journal of Clinical Nutrition, 2011
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- Prednisone, Lupus Activity, and Permanent Organ DamageThe Journal of Rheumatology, 2009
- Assessing Risk of Bias in Included Studies2008
- Treatment‐free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamideArthritis & Rheumatism, 1994